Status:
COMPLETED
Digestibility of Fermotein™
Lead Sponsor:
Wageningen University and Research
Collaborating Sponsors:
The Protein Brewery
Conditions:
Digestive System
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
This study aims to assess the degree of digestibility of 3 different Fermotein™ products and compare this to a reference commercially available Mycoprotein (Quorn) and to assess the effects on blood g...
Detailed Description
Mycoprotein is a protein source derived from fungi produced for human consumption. It is high in protein, high in fiber, low in saturated fat and contains no cholesterol. Their functional properties a...
Eligibility Criteria
Inclusion
- Apparently healthy men and women;
- Age between 18 and 70 years;
- Body mass index (BMI) between 18.5 and 30 kg/m2 ;
- Having veins suitable for blood sampling via a catheter (judged by study nurse/ medical doctor).
Exclusion
- Any metabolic, gastrointestinal, inflammatory or chronic disease (such as diabetes, anaemia, hepatitis, cardiovascular disease),or having a condition or disease that may lead to an impaired immune system
- History of gastrointestinal surgery or having (serious) gastrointestinal complaints;
- History of liver dysfunction (cirrhosis, hepatitis) or liver surgery;
- Kidney dysfunction (self-reported);
- Any use of medication that may suppress the immune system, this will be judged by the medical supervisor;
- Use of medication that may influence the study results, such as gastric acid inhibitors, laxatives, stomach protectors and drugs that can affect intestinal motility, this will be judged by the medical supervisor;
- Anaemia (Hb values \<7.5 mmol/L for women and \<8.5 mmol/L for men);
- Reported slimming, medically prescribed or other extreme diets;
- Not willing to give up blood donation during the study;
- Current smokers;
- Alcohol intake ≥4 glasses of alcoholic beverages per day;
- Pregnant, lactating or wishing to become pregnant in the period of the study (self-reported);
- Abuse of hard drugs;
- Having food allergies;
- Not having a general practitioner;
- Participation in another clinical trial at the same time;
- Being an employee of the department Food, Health \& Consumer Research of Wageningen Food \& Biobased Research.
Key Trial Info
Start Date :
April 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04819789
Start Date
April 13 2021
End Date
May 20 2021
Last Update
May 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stichting Wageningen Research
Wageningen, Gelderland, Netherlands, 6708 WG